Back to list

Safety and effectiveness of insulin analogues in Moroccan patients with type 2 diabetes: a sub-analysis of the A1chieve study

Abdelmjid Chraibi a * , Farida Ajdi b, Jamal Belkhadir c, Naoual El Ansari d, Fatima Marouan e and Ahmed Farouqi f

Diabetes Research and Clinical Practice, pages S27 - S36

Published online Aug-2013


Article view:

Abstract

Aim

To determine the safety and effectiveness of insulin analogues in the Moroccan cohort of the prospective, multinational, non-interventional, 24-week A1chieve study.

Methods

Moroccan patients with type 2 diabetes (T2D) starting biphasic insulin aspart 30, insulin detemir, and insulin aspart alone or in combination were included. The primary outcome was the evaluation of serious adverse drug reactions including major hypoglycaemic events. Secondary outcomes were changes in hypoglycaemic events, glycaemic parameters (HbA1c, fasting plasma glucose [FPG], postprandial plasma glucose [PPPG]), systolic blood pressure (SBP), body weight and lipid profile. Quality of life (QoL) was evaluated using the EQ-5D questionnaire.

Results

In this analysis, 1641 patients (923 insulin-naive, 718 insulin-experienced) having a mean age 57.1 years, mean BMI 26.8 kg/m2 and mean diabetes duration 10.3 years, were included. Baseline HbA1c in the entire cohort was poor (9.7%, 83 mmol/mol). Insulin analogues statistically significantly improved glucose control (HbA1c, FPG and PPPG, p < 0.001) at Week 24. The rate of hypoglycaemia decreased from 9.31 to 4.71 events/patient-year (change in proportion of patients affected, p = 0.0002). A statistically significant improvement in lipid parameters (except HDL cholesterol) was observed while body weight changed minimally. Additionally, QoL was positively impacted (mean change in visual analogue scores from EQ-5D was 15.8 points, p < 0.001).

Conclusions

Insulin analogue therapy resulted in improved glycaemic control and a significant overall decrease in hypoglycaemia in Moroccan T2D patients.

Keywords: Morocco, Type 2 diabetes, Insulin analogues, A1chieve study.


Article Outline

References

  • 1 L Nahid, K Abdelilah. Towards a better future in Morocco. Diabetes Voice. 2006;51(3):16-17
  • 2 DR Whiting, L Guariguata, C Weil, J Shaw. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diab Res Clin Pract. 2011;94:311-321 Crossref.
  • 3 MA Tazi, S Abir-Khalil, N Chaouki, S Cherqaoui, F Lahmouz, JE Sraïri, et al. Prevalence of the main cardiovascular risk factors in Morocco: results of a national survey in 2000. J Hypertens. 2003;21(5):897-903 Crossref.
  • 4 A Alwan, H King. Diabetes in the Eastern Mediterranean (Middle East) region: the World Health Organization responds to a major public health challenge. Diabet Med. 1995;12(12):1057-1058 Crossref.
  • 5 S Benjelloun. Nutrition transition in Morocco. Public Health Nutr. 2002;5(1A):135-140
  • 6 AO Musaiger, HM Al-Hazzaa. Prevalence and risk factors associated with nutrition-related noncommunicable diseases in the Eastern Mediterranean region. Int J Gen Med. 2012;5:199-217 Crossref.
  • 7 SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577-1596 Crossref.
  • 8 P Valensi, M Benroubi, V Borzi, J Gumprecht, R Kawamori, J Shaban, et al., on behalf of the IMPROVE™ Study Group Expert Panel. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE™ observational study. Int J Clin Pract. 2009;63(3):522-531 Crossref.
  • 9 D Khutsoane, SK Sharma, M Almustafa, HC Jang, ST Azar, R Danciulescu, et al., PRESENT Study Group. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab. 2008;10(3):212-222 Crossref.
  • 10 P Home, NE Naggar, M Khamseh, G Gonzalez-Galvez, C Shen, P Chakkarwar, et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study. Diabetes Res Clin Pract. 2011;94(3):352-363 Abstract, Full-text, PDF, Crossref.
  • 11 C Fajardo Montañana, C Hernández Herrero, M Rivas Fernández. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabet Med. 2008;25(8):916-923
  • 12 A Philis-Tsimikas, G Charpentier, P Clauson, GM Ravn, VL Roberts, B Thorsteinsson. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28(10):1569-1581 Crossref.
  • 13 A Liebl, R Prager, K Binz, M Kaiser, R Bergenstal, B Gallwitz, PREFER Study Group. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab. 2009;11(1):45-52 Crossref.
  • 14 M Korytkowski. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26(Suppl 3):S18-S24 Crossref.
  • 15 JN Henderson, KV Allen, IJ Deary, BM Frier. Hypoglycaemia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med. 2003;20(12):1016-1021 Crossref.
  • 16 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853
  • 17 Action to control cardiovascular risk in Diabetes study group, HC Gerstein, ME Miller, RP Byington, DC Goff Jr, JT Bigger, et al. Effects of intensive glucose lowering in type 2 diabetes. N Eng J Med. 2008;358(24):2545-2559
  • 18 RR Rubin, M Peyrot. Quality of life and diabetes. Diabetes Metab Res Rev. 1999;15(3):205-218 Crossref.

Footnotes

a Diabetes, Endocrinology and Nutrition Department, Ibn Sina Hospital, Mohammed V Souissi University, Rabat, Morocco Diabetes, Endocrinology and Nutrition Department, Ibn Sina Hospital, Mohammed V Souissi University, Rabat, Morocco

b Diabetes, Endocrinology and Nutrition Department, Hassan II University Hospital, Fes, Morocco Diabetes, Endocrinology and Nutrition Department, Hassan II University Hospital, Fes, Morocco

c Professor of Diabetes, Endocrinology and Nutrition, 28, avenue de France, appt. 8 3 ét., 10090, Rabat, Morocco Professor of Diabetes, Endocrinology and Nutrition, 28, avenue de France, appt. 8 3 ét., Rabat, 10090, Morocco

d Diabetes, Endocrinology and Nutrition Department, Ibn Tofail Hospital, Mohammed VI University Hospital, Marrakech, Morocco Diabetes, Endocrinology and Nutrition Department, Ibn Tofail Hospital, Mohammed VI University Hospital, Marrakech, Morocco

e Professor of Diabetes, Endocrinology and Nutrition, Rue Al Hassan Azzaafrani Villa Delice, Casablanca, Morocco Professor of Diabetes, Endocrinology and Nutrition, Rue Al Hassan Azzaafrani Villa Delice, Casablanca, Morocco

f Diabetes, Endocrinology and Nutrition Department, Ibn Rochd University Hospital, Casablanca, Morocco Diabetes, Endocrinology and Nutrition Department, Ibn Rochd University Hospital, Casablanca, Morocco

* Corresponding author at: Diabetes, Endocrinology and Nutrition Department, Ibn Sina Hospital, Mohammed V Souissi University, Rabat, Morocco. Tel.: +212661294916; fax: +212522200641

Back to list